Cabaletta Bio Files 8-K on Financials and Operations

Ticker: CABA · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1759138

Sentiment: neutral

Topics: financial-reporting, operations, sec-filing

Related Tickers: CRTX

TL;DR

Cabaletta Bio dropped an 8-K detailing financials and operations. Check it out.

AI Summary

Cabaletta Bio, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes information related to Regulation FD disclosure, other events, and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Philadelphia, PA.

Why It Matters

This 8-K filing provides investors with crucial updates on Cabaletta Bio's financial health and operational developments, impacting their investment decisions.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for reporting financial and operational information, not indicating any immediate adverse events.

Key Numbers

Key Players & Entities

FAQ

What specific financial results are detailed in this 8-K?

This 8-K filing indicates it covers 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.

Are there any material events reported beyond routine financial disclosures?

The filing lists 'Other Events' as a category, but the specific nature of these events is not detailed in the provided text.

What is the primary business of Cabaletta Bio, Inc.?

Cabaletta Bio, Inc. is in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' industry, as indicated by its SIC code.

Where is Cabaletta Bio, Inc. headquartered?

Cabaletta Bio, Inc. is headquartered at 2929 Arch Street, Suite 600, Philadelphia, PA 19104.

What is the significance of the 'Regulation FD Disclosure' item?

This indicates that the filing includes information that may be subject to Regulation Fair Disclosure, ensuring broad public dissemination of material non-public information.

Filing Stats: 2,465 words · 10 min read · ~8 pages · Grade level 17.1 · Accepted 2025-01-13 08:10:28

Key Financial Figures

Filing Documents

Forward-Looking Statements

Forward-Looking Statements The information under this Item 8.01 contains "forward-looking statements" of Cabaletta Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, express or implied statements regarding: Cabaletta's business plans and objectives as a whole; Cabaletta's ability to realize its vision of launching the first curative targeted cell therapy designed specifically for patients with autoimmune diseases; Cabaletta's ability to successfully complete research and further development and commercialization of its drug candidates in current or future indications, including the timing and results of Cabaletta's clinical trials and its ability to conduct and complete clinical trials; expectation that clinical results will support rese-cel's safety and activity profile; statements regarding the timing of interactions with regulatory authorities, including such authorities' review of safety information from Cabaletta's ongoing clinical trials and potential registrational pathway for rese-cel; Cabaletta's expectations around the potential success and therapeutic benefits of rese-cel, including its belief that rese-cel has the potential to reset the immune system and result in compelling clinical responses without chronic therapy requirements in patients; the Company's advancement of separate Phase 1/2 clinical trials of rese-cel in patients with SLE, myositis, SSc and gMG and advancement of the RESET-PV and RESET-MS trials, including updates related to status, safety data, efficiency of clinical trial design and timing of data read-outs or otherwise; the clinical significance of the clinical data read-out at upcoming scientific meetings; Cabaletta's ability to expand its clinical supply for registrational trial(s) across the RESET clinical development program as well as to expand its manufacturing options for rese-cel; Cabaletta's ability to increase enrollment in its US and Europe clinical net

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits 99.1 Corporate Presentation, dated January 13, 2025, furnished herewith. 99.2 Press Release issued by the registrant on January 13, 2025, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CABALETTA BIO, INC. Date: January 13, 2025 By: /s/ Steven Nichtberger Steven Nichtberger, M.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing